The adoption of its GI endomicroscopy technology could also trigger an estimated additional $9.5 billion in overall healthcare benefits in the US, according to research Optiscan commissioned last year from US-based consultants Latham Biopharm Group.
The information collected from the Gen2 trials will allow Optiscan’s engineers – under professor Keisslich’s guidance – to develop a third-generation (Gen3) flexible endomicroscope. Optiscan expects Gen3 to be ready in the coming year and will use it in any subsequent clinical trials.
As part of its longer-term planning, the company is also investigating the use of artificial intelligence (AI) to improve early disease detection. In collaboration with Monash University, it is collecting and analysing imaging data from a range of GI diseases. The partnership is part of an Australian federal government-backed Co-operative Research Centres project grant worth $3 million.
Optiscan says its AI-driven approach has the potential to push diagnostic accuracy to new heights, making way for faster and more precise medical diagnoses of GI disease, including colorectal cancer, which is the second-leading cause of cancer-related deaths worldwide.
GI diseases present a huge health challenge around the world. Traditional diagnostic methods often involve invasive procedures and long waits for lab results, delaying critical findings.
Optiscan says its technology should instead deliver real-time, high-resolution imaging at a single cell level, allowing much more precise and real-time results.
As the demand for digital health solutions continues to grow, Optiscan’s innovative approach appears to be positioning the company as a key player in the future of real-time, less invasive medical imaging.
Is your ASX-listed company doing something interesting? Contact: [email protected]
- For more: Elrisala website and for social networking, you can follow us on Facebook
- Source of information and images “brisbanetimes”“
